Search

Search Constraints

You searched for: Author/Creator Michaelson, M. Dror

Search Results

1. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. (6th June 2019)

2. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. (6th September 2018)

3. Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. (16th February 2022)

4. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. (May 2018)

5. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. (9th August 2019)

6. Characterizing fatigue associated with sunitinib and its impact on health‐related quality of life in patients with metastatic renal cell carcinoma. Issue 12 (13th March 2014)

7. Characterizing fatigue associated with sunitinib and its impact on health‐related quality of life in patients with metastatic renal cell carcinoma. Issue 12 (13th March 2014)

8. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115–125]. (November 2018)